Previous 10 | Next 10 |
Image source: The Motley Fool. Inogen Inc (NASDAQ: INGN) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading
Inogen, Inc. (INGN) Q4 2019 Earnings Conference Call February 25, 2020 04:30 PM ET Company Participants Matt Bacso - IR Scott Wilkinson - CEO Ali Bauerlein - CFO Conference Call Participants Margaret Kaczor - William Blair Danielle Antalffy - SVB Leerink Mike Matson - N...
Inogen (NASDAQ: INGN ): Q4 GAAP EPS of -$0.06 misses by $0.16 . More news on: Inogen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Inogen, Inc. (NASDAQ: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month and twelve-month periods ended December 31, 2019. Fourth Quarter 2019 Highlights Total reve...
Inogen, Inc. (NASDAQ: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the 9 th Annual Leerink Partners Global Healthcare Conference in New York City...
Inogen, Inc . (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release fourth quarter and full year 2019 financial results after market close on Tuesday, February 25, 2020. The Company will host a ...
"Stocks always go down faster than they go up, but they always go up more than they go down." Long-term investors will probably recognize this old market truism -- maybe even from their own personal and painful experience of the "go down" part. But investors who've stuck around in the marke...
Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP ) +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...
Inogen (NASDAQ: INGN ) -18.2% pre-market after saying it expects Q4 revenues of $78.4M-$79.4M based on preliminary data, down 8.2%-9.4% from the year-ago quarter, citing softer than expected demand primarily in its direct-to-consumer and international channels. More news on: Inogen, In...
– Q4 2019 Total Preliminary Revenue of $78.4 to $79.4 million – – Updates 2020 Guidance – Inogen, Inc. (NASDAQ: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported prelimin...
News, Short Squeeze, Breakout and More Instantly...
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2024 financial results after the market closes on Tuesday, August 6, 2024. On the same day, the Company wil...
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith jo...